The study examined the impact of immunotherapy on overall survival (OS) in rectal cancer patients using a propensity score matched analysis of the National Cancer Database. Out of the total patients analyzed, only 2.5% underwent immunotherapy. The results showed that patients treated with immunotherapy had shorter OS compared to controls. However, when stratified by clinical stage, immunotherapy was associated with improved OS in stage IV patients while lower survival in stage II and III patients. These findings suggest that immunotherapy may have a modest benefit in stage IV metastatic rectal cancer but not in earlier stages.
Journal Article by Horesh N, Emile SH (…) Wexner SD et 4 al. in Int J Colorectal Dis
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.